With the burgeoning interest in innovative treatments for type 2 diabetes and weight management, a head-to-head evaluation of Mounjaro and the dual GIP and GLP-1 receptor agonist has become paramount. While both drugs function through related mechanisms – affecting glucagon-like peptide-1 and GIP sites – key variations in their structure and re